It’s not known whether Cosentyx (secukinumab ... or appropriate for all patients or all specific uses.
IL-17 inhibitor Cosentyx (secukinumab) is already approved by NICE to treat ankylosing spondylitis or radiographic axial spondyloarthritis (r-axSpA) – another form of spinal arthritis that ...